These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

892 related articles for article (PubMed ID: 11221874)

  • 1. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
    Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
    Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
    Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
    Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
    Saha A; Chatterjee SK
    Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
    Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
    Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
    Gu XG; Schmitt M; Hiasa A; Nagata Y; Ikeda H; Sasaki Y; Akiyoshi K; Sunamoto J; Nakamura H; Kuribayashi K; Shiku H
    Cancer Res; 1998 Aug; 58(15):3385-90. PubMed ID: 9699670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
    Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity.
    Eck SC; Turka LA
    Cancer Res; 2001 Apr; 61(7):3077-83. PubMed ID: 11306490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.
    Chen Y; Hu D; Eling DJ; Robbins J; Kipps TJ
    Cancer Res; 1998 May; 58(9):1965-71. PubMed ID: 9581840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.